Pharmaceutical products

Contract Value:: PLN 36M - 36M
Notice Type:: Contract Notice

Published Date:: 18 November 2022
Closing Date:: 21 December 2022

Location(s):: PL911 Miasto Warszawa (PL Poland/POLSKA)

Description:

Supply of medicinal products for chemotherapy, drug programs

purchase and supply of Vedolizumab

The quality requirements of medicinal products are specified in the Act of 6 September 2001 - Pharmaceutical Law (i.e. Journal of Laws of 2020, item 944), which in Art. Article 1(1)(1) provides that it lays down, m.in, the rules and procedures for the authorisation of medicinal products, taking into account, in particular, the requirements relating to the quality, efficacy and safety of their use.' In addition, the Regulation of the Minister of Health of 9 November 2015 on the requirements of Good Manufacturing Practice (Journal of Laws of 2019, item 728 of późn.zm) specifies in detail the requirements for ensuring the appropriate quality of the medicinal product. In the proceedings in question, the quality requirements of medicinal products have been defined by the Ordering Party by specifying in the description of the subject of the contract which includes, m.in. composition, form and route of administration and unit of measurement.

purchase and successive delivery of the medicinal product Bicalutamid

purchase and successive delivery of the medicinal product urapidyl

purchase and successive delivery of the medicinal product Cyclosporin

purchase and successive delivery of ONS diets

purchase and successive delivery of ons ons part 2

purchase and successive delivery of the medicinal product Meropenem

purchase and successive supply of medicinal products everolimus

purchase and successive delivery of ONS diets part 3

Purchase and successive delivery of Vaccines

purchase and successive delivery of the medicinal product Zoledronic acid

purchase and successive delivery of the medicinal product Parikalcytol

purchase and successive delivery of the medicinal product Aflibercept

purchase and successive delivery of the medicinal product Cisplatinum

purchase and successive delivery of the medicinal product Paclitaxel

purchase and successive delivery of the medicinal product Sorafenib

purchase and successive supply of ribociclib

purchase and successive delivery of the medicinal product dimethyl fumarate

purchase and successive delivery of the medicinal product darbepoietin alfa

purchase and successive delivery of the medicinal product Durvalumabum

purchase and successive delivery of the medicinal product Epoetinum alfa

purchase and successive delivery of the medicinal product Lanreotide

purchase and successive delivery of the medicinal product oxaliplatin

purchase and successive delivery of the medicinal product Gemcitabinum

purchase and successive supply of medicinal products Tocilizumab, obinutuzumab and others

purchase and successive delivery of the medicinal product peginterferon beta -1A

purchase and successive delivery of Mercaptopurinum

purchase and successive delivery of cytarabina

purchase and successive delivery of the medicinal product Filgrastimum

purchase and successive supply of medicinal products okrelizumab

purchase and successive delivery of Lenalidomid

purchase and successive supply of carboplatin

purchase and successive delivery of Macitentan

purchase and successive delivery of Natalizumab medicinal products

purchase and successive delivery of tofacitinib

purchase and successive delivery of the medicinal product Aprepitant

purchase and successive delivery of the medicinal product Chlorambucil

purchase and successive delivery of medicinal products illoprost

purchase and successive delivery of the medicinal product Interferonum beta -1A

purchase and successive delivery of interferon beta 1A

purchase and successive delivery of the medicinal product Lapatinibum

purchase and successive delivery of Sekukinumab

purchase and successive delivery of the medicinal product Darbepoetinum

purchase and successive delivery of the medicinal product Aflibercept

purchase and successive delivery of the medicinal product ondansetron

purchase and successive delivery of the medicinal product Ciclosporinum

purchase and successive supply of the medicinal product teriflunomide

purchase and successive delivery of Kabozantinib

purchase and successive delivery of the medicinal product Bosentanum

purchase and successive delivery of the medicinal product folinic acid in the form of calcium folate

purchase and successive delivery of the medicinal product Adalimumab

purchase and successive delivery of the medicinal product Everolimus

purchase and successive delivery of the medicinal product Melphelan

purchase and successive delivery of the medicinal product Panitumumab

purchase and successive delivery of the medicinal product Netupitant + palonosetron

purchase and successive delivery of the medicinal product imatinib

purchase and successive delivery of the medicinal product pemetrexedum

purchase and successive delivery of Carfilzomib

purchase and successive delivery of the medicinal product Alektynib

purchase and successive supply of the medicinal product Upadacitinibum

purchase and successive delivery of Nintedanib

purchase and successive delivery of the medicinal product alprostadil

purchase and successive delivery of propofolum

purchase and successive delivery of the medicinal product Abirateroni acetas

purchase and successive delivery of Dexamethasone sodium phosphate inj

purchase and successive delivery of Trombinum

purchase and successive delivery of the medicinal product Phenylephrine

purchase and successive delivery of the product cefiderokol

purchase and successive supply of the medicinal product dobutaminum

purchase and successive delivery of the medicinal product drotaverine i.v.

purchase and successive delivery of Gadobenic acid

purchase and successive supply of potable substances

purchase and successive delivery of cefepime

purchase and successive delivery of the medicinal product Metronidazole i.v.

purchase and successive delivery of the medicinal product Palbocylib

purchase and successive delivery of the medicinal product fosfomycin

Purchase and successive delivery of medicinal products

Purchase and Successive Delivery of Argipresine

purchase and successive delivery of the medicinal product fibrinogen

purchase and successive supply of the medicinal product protamine sulphate

purchase and successive supply of the medicinal product fluconazole

purchase and successive delivery of Antithrombin III

purchase and successive delivery of the medicinal product thiamine

purchase and successive supply of the medicinal product short-acting insulin

purchase and successive delivery of the medicinal product insulin analogues

purchase and successive delivery of trastuzumab

purchase and successive delivery of the medicinal product analogue of fast-acting insulin

purchase and successive delivery of the medicinal product insulin analogue c.d

purchase and successive delivery of the insulin analogue medicinal product

purchase and successive delivery of Imipenem with cilastin

purchase and successive delivery of a medicinal product

purchase and successive delivery of the medicinal product Amikacin

purchase and successive delivery of the medicinal product Kaspofungin

purchase and successive supply of medicinal products allergen extract of fibrowing insects

purchase and successive delivery of the medicinal product Paracetamol I.V.

purchase and successive delivery of the medicinal product cisatracurium

purchase and successive delivery of the medicinal product peginterferon alfa -2A

purchase and successive delivery of the medicinal product ceftasidym + awibaktam

purchase and successive delivery of Vancomycin

purchase and successive delivery of the medicinal product - tissue glue

purchase and successive delivery of the medicinal product potasium chloride inj

purchase and successive delivery of the medicinal product fibrinogen + thrombin

purchase and successive supply of medicinal products of membrane-winged insect venom for tests and non-specific immunotherapy

purchase and successive delivery of medicinal products for parenteral nutrition

purchase and successive supply of medicinal products vancomycin for intravenous and oral supply

purchase and successive delivery of the medicinal product Suxamehtonium chloride

purchase and successive delivery of the medicinal product rifaximin

: Download full details as .pdf

The Buyer:: Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie

CPV Code(s):: 09221100 - Petroleum jelly; 15880000 - Special nutritional products; 15882000 - Dietetic products; 24313300 - Carbonates; 33600000 - Pharmaceutical products; 33612000 - Medicinal products for functional gastrointestinal disorders; 33614000 - Antidiarrhoeals, intestinal anti-inflammatory/anti-infective agents; 33615100 - Insulin; 33616000 - Vitamins; 33621100 - Antithrombotic agents; 33621200 - Antihaemorrhagics; 33621300 - Antianaemic preparations; 33621400 - Blood substitutes and perfusion solutions; 33622100 - Cardiac therapy medicinal products; 33622200 - Antihypertensives; 33631600 - Antiseptics and disinfectants; 33632000 - Medicinal products for the musculo-skeletal system; 33632200 - Muscle relaxants; 33642000 - Systemic hormonal preparations, excl. sex hormones; 33642100 - Pituitary, hypothalamic hormones and analogues; 33642200 - Corticosteroids for systemic use; 33651100 - Antibacterials for systemic use; 33651200 - Antimycotics for systemic use; 33651610 - Diphtheria-pertussis-tetanus vaccines; 33652000 - Antineoplastic and immunomodulating agents; 33652100 - Antineoplastic agents; 33652200 - Endocrine therapy medicinal products; 33652300 - Immunosuppressive agents; 33661100 - Anaesthetics; 33661200 - Analgesics; 33661500 - Psycholeptics; 33674000 - Cough and cold preparations; 33690000 - Various medicinal products; 33695000 - All other non-therapeutic products; 33696000 - Reagents and contrast media